SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-16-009151
Filing Date
2016-11-03
Accepted
2016-11-03 08:31:00
Documents
60
Period of Report
2016-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q acrs-20160930x10q.htm 10-Q 1351589
2 EX-31.1 acrs-20160930ex3116cf9d3.htm EX-31.1 14097
3 EX-31.2 acrs-20160930ex312445f95.htm EX-31.2 14083
4 EX-32.1 acrs-20160930ex321eb7f0a.htm EX-32.1 10675
  Complete submission text file 0001558370-16-009151.txt   5760429

Data Files

Seq Description Document Type Size
5 EX-101.INS acrs-20160930.xml EX-101.INS 1362040
6 EX-101.SCH acrs-20160930.xsd EX-101.SCH 34873
7 EX-101.CAL acrs-20160930_cal.xml EX-101.CAL 41018
8 EX-101.DEF acrs-20160930_def.xml EX-101.DEF 134247
9 EX-101.LAB acrs-20160930_lab.xml EX-101.LAB 382275
10 EX-101.PRE acrs-20160930_pre.xml EX-101.PRE 269457
Mailing Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355
Business Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355 484-321-5554
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37581 | Film No.: 161970270
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences